Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06261060 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
A Phase 2 study of Familial Platelet Disorder and Hematopoietic, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06261060: Recruiting Phase 2 study of Familial Platelet Disorder and Hematopoietic, sponsored by M.D. Anderson Cancer Center.
NCT06261060 is a Phase 2 study of Familial Platelet Disorder and Hematopoietic that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06261060, a Phase 2 study of Familial Platelet Disorder and Hematopoietic, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2028-06-11 |
| Phase | Phase 2 |
What NCT06261060 shows while recruiting
NCT06261060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Familial Platelet Disorder appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT06261060 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06261060 about?
NCT06261060 is a clinical study titled "Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder". To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
What is the current status of trial NCT06261060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2024-06-20. Estimated completion is 2028-06-11.
What conditions does trial NCT06261060 study?
This clinical trial studies the following conditions: Familial Platelet Disorder, Hematopoietic.
What interventions are being tested in trial NCT06261060?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT06261060?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06261060 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06261060's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI